According to the Zhitong Finance App, Hualing Pharmaceutical-B (02552) announced its 2026 interim results. The group achieved revenue of HK$379 million, an increase of 74.26% over the previous year, with a net loss of $30.195 million and a loss of $0.03 per share.

In the first half of 2026, the company made solid progress in the commercialization-led organizational transformation. Huatangning® entered a phase of rapid scale-up and achieved strong sales growth. The expansion of production scale and improvement in commercial operation efficiency have drastically reduced the company's net loss.

In the first half of 2026, the company sold approximately 3,055,000 boxes of Huatangning®, an increase of 73% over the 1,764,000 boxes sold during the same period in 2025. The trend of rapid sales growth was further supported by the fact that prices in China's national medical insurance drug catalogue remained unchanged for the 2026 and 2027 calendar years.

As the company's commercialization team and hospital coverage continued to expand, revenue increased 74% year-on-year to 378.9 million yuan, reflecting the effectiveness of the company's independent commercialization strategy.

The increase in production scale and efficiency greatly increased gross margin to 61.8% during the period, far higher than 54.2% in the same period last year.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.